On September 24th, the Board of NEUCA S.A. signed a significant investment agreement with Viking Global Investors, a global Investment firm based in the United States. Under the agreement, Viking purchased a minority share package in Humaneva Inc., a company spun off from NEUCA S.A., for $50 million USD. Additionally, Viking received an annual option to invest an additional $50 million USD in Humaneva Inc. The transaction will contribute to the implementation of a long-term strategy in the field of clinical trials.
In the personnel area in the first quarter, Bartosz Józefiak (ex-CFO of Benefit Systems) joined the Humaneva Inc. team as a Board Member for Financial Affairs.
Humaneva Inc., the dominant company of Pratia, Kapadi, and Hyggio – the market leaders of integrated solutions in the field of clinical trials – plans to accelerate the development of its business model. As a major player in the European market, the group now intends primarily to focus on expansion in the American market and in the APAC region, which are recognized centres for advanced clinical trials. With over 90 dedicated and integrated clinical research centres, Humaneva also plans to strengthen its own technology offering, focusing on eSource solutions, data integration, and analysis, in order to expand access to clinical trials as a therapeutic option for patients worldwide.
“The clinical trials market is evolving with incredible dynamism, characterized by international scale consolidation and the constant emergence of innovative business models. Strategically, cooperation with Viking is a milestone for us in further development. Viking’s unique mix of experience and practice in hedge funds and private equity, combined with a long-term perspective of value building, aligns perfectly with Humaneva’s vision,” said Tomasz Dąbrowski, President of the Humaneva Inc. Board. “The United States accounts for nearly 80% of the expenditure on research and development in the clinical trials market. Strengthening our position, especially in the U.S., will allow us to increase the scale of operations and capabilities in the coming years,” he added.
Humaneva stands out with its direct access to patients, strong focus on oncology, advanced data management, and proprietary technology that integrates processes between clinical research centres, study sponsors, and CRO companies. This innovative approach allows projects to be implemented more efficiently, optimizing processes and reducing redundant tasks that affect the time, quality, and consistency of data. As a result, study sponsors benefit from lower molecule development costs, shortening the time to market and increasing efficiency.
“Apart from the financial aspect related to obtaining funds for the development of the clinical trials segment in the NEUCA Group, cooperation with our new partner could potentially result in new contacts and greater trust from American market companies in our company. This transaction also demonstrates the high potential of the area and the long-term prospects of the Group, while also validating our actions to date and confirming the validity of the growth direction we have chosen for the segment. We believe that together with Viking we will effectively build value for Humaneva shareholders, and thus for the NEUCA Group,” said Grzegorz Dzik, Vice President of the Board of NEUCA S.A.
Source: https://managerplus.pl/neuca-pozyskuje-strategicznego-inwestora-viking-global-investors-inwestuje-50-mln-usd-w-humaneva-inc-49136
